Core Viewpoint - Altimmune, Inc. (ALT) has shown a significant price increase of 28.4% over the past four weeks, with a mean price target of $17.88 indicating a potential upside of 229.3% from the current price of $5.43 [1] Price Targets and Analyst Consensus - The average price target for ALT includes eight short-term estimates ranging from a low of $1.00 to a high of $28.00, with a standard deviation of $8.81, indicating variability in analyst predictions [2] - The lowest estimate suggests a decline of 81.6%, while the highest points to an upside of 415.7% [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price direction, which can be a useful starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about ALT's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.8%, with one estimate moving higher and no negative revisions [12] - ALT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While the consensus price target is a commonly referenced metric, relying solely on it for investment decisions may not be prudent due to historical inaccuracies in predicting actual stock price movements [3][7] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8] - Investors should approach price targets with skepticism and consider them as one of many factors in their decision-making process [10]

Core Viewpoint - Evolv Technologies Holdings, Inc. (EVLV) shares have seen a 0.7% increase over the past four weeks, closing at $6.77, with a potential upside of 45.9% based on Wall Street analysts' mean price target of $9.88 [1][2] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $0.25, indicating a consensus among analysts. The lowest estimate of $9.50 suggests a 40.3% increase, while the highest target of $10.00 indicates a 47.7% increase [2] - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about EVLV's earnings prospects, as indicated by a positive trend in earnings estimate revisions. The Zacks Consensus Estimate for the current year has increased by 15% over the past month, with no negative revisions [11][12] - EVLV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside in the near term [13] Caution on Price Targets - While the consensus price target is a commonly referenced metric, it should not be the sole basis for investment decisions due to the questionable reliability of analysts in setting these targets [3][10] - Analysts may set overly optimistic price targets influenced by business relationships, which can lead to inflated expectations [8]

McGraw Hill, Inc. (MH) closed the last trading session at $16.68, gaining 51% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $20.92 indicates a 25.4% upside potential.The average comprises 12 short-term price targets ranging from a low of $16.00 to a high of $26.00, with a standard deviation of $2.71. While the lowest estimate indicates a decline of 4.1% from the current price lev ...

Tetra Tech (TTEK) closed the last trading session at $33.58, gaining 4.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $42.4 indicates a 26.3% upside potential.The average comprises five short-term price targets ranging from a low of $38.00 to a high of $48.00, with a standard deviation of $3.65. While the lowest estimate indicates an increase of 13.2% from the current price lev ...

CorMedix (CRMD) closed the last trading session at $11.26, gaining 1.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $19 indicates a 68.7% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $3.11. While the lowest estimate of $14.00 indicates a 24.3% increase from the current price level, the most optimistic analyst expects t ...

Oculis Holding AG (OCS) closed the last trading session at $21.68, gaining 12.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $44.67 indicates a 106% upside potential.The average comprises nine short-term price targets ranging from a low of $29.00 to a high of $55.07, with a standard deviation of $9.51. While the lowest estimate indicates an increase of 33.8% from the current pr ...

Pony AI Inc. - Sponsored ADR (PONY) closed the last trading session at $14.2, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $24.23 indicates a 70.6% upside potential.The average comprises seven short-term price targets ranging from a low of $20.00 to a high of $32.79, with a standard deviation of $5.59. While the lowest estimate indicates an increase of 40.9% from th ...

Core Viewpoint - On Holding (ONON) shares have increased by 37.5% in the past four weeks, closing at $48.14, with a mean price target of $60.71 indicating a potential upside of 26.1% [1] Price Targets and Analyst Estimates - The mean estimate consists of 21 short-term price targets with a standard deviation of $10.43, where the lowest estimate is $30.00 (indicating a 37.7% decline) and the highest is $85.00 (indicating a 76.6% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Consensus - Analysts are optimistic about ONON's earnings prospects, as indicated by a strong agreement in revising EPS estimates higher, which correlates with near-term stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 88.1%, with six estimates moving higher and one lower [12] - ONON holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While consensus price targets are often sought after, they may mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Tango Therapeutics, Inc. (TNGX) closed the last trading session at $9.63, gaining 22.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13.22 indicates a 37.3% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $1.39. While the lowest estimate of $11.00 indicates a 14.2% increase from the current price level, the most optimistic ...

Core Viewpoint - Mineralys Therapeutics, Inc. (MLYS) has seen a 5.1% increase in share price over the past four weeks, closing at $38.91, with a potential upside of 27.6% based on Wall Street analysts' mean price target of $49.63 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $42.00 to a high of $56.00, with a standard deviation of $5.78, indicating variability among analysts [2] - The lowest estimate suggests a 7.9% increase from the current price, while the highest estimate indicates a 43.9% upside [2] Analyst Consensus and Earnings Estimates - Analysts are increasingly optimistic about MLYS's earnings prospects, as evidenced by a strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [4][11] - Over the last 30 days, three earnings estimates have been revised upward, leading to a 6.7% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank - MLYS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Price Movement Guidance - While the consensus price target may not be a reliable indicator of the extent of MLYS's potential gains, the implied direction of price movement appears to be a useful guide for investors [14]